Paul Spittle joined the Sanofi team as chief commercial officer for general medicines in March 2021, having previously worked in numerous big pharma companies around the world, including Merck & Co., Inc., Novartis AG and AstraZeneca PLC. He was attracted to Sanofi because of the commercial model transformation the company is aiming for in its general medicines business unit.
Inside Sanofi’s General Medicines Unit: Embracing A New Commercial Model
Sanofi’s general medicines business will embrace an omnichannel commercial model in 2022 to reduce inefficiencies and stabilize topline growth. Virtual sales reps are on the rise after a tough couple of years managing product promotion and launches online only.
More from Outlook Archive
• By
Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.
• By
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
• By
Pfizer catapulted back into the lead in the pharmaceutical rankings on the strength of COVID-19 revenues while BioNTech and Moderna both made the list for the first time.
• By
What will 2023 bring as the industry faces one of the toughest periods in the last decade? In Vivo asked three industry experts for their views.
More from Outlook
• By
Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.
• By
Nine biopharma companies made 12 or more deals, with Novartis inking 21 deals and leading M&A activity. Roche, meanwhile, spent little up front but maintained a hectic pace with 12 alliances.
• By
As Eli Lilly and Novo Nordisk reap the blockbuster rewards of their rival obesity therapies the companies are also bulking up their organizations to make the most of the phenomenal rise of the GLP-1 class.